BACKGROUND: There is increasing evidence that stromal cell interactions are required for the survival and drug resistance of several types of B-cell malignancies. There is relatively little information regarding the role of the bone marrow/lymphoid microenvironment in the pathogenesis of mantle cell lymphoma. In this study we investigated the interaction of primary mantle cell lymphoma cells with stromal cells in an ex vivo co-culture system. DESIGN AND METHODS: The murine stromal cell line MS-5 and human bone marrow mesenchymal stromal cells were each co-cultured with primary mantle cell lymphoma cells for up to 7 months. Mantle cell lymphoma cultures alone or combined with human stromal cells were analyzed for cell number, cell migration, nuclear factor-κB activation and drug resistance. RESULTS: Co-culture of mantle cell lymphoma cells and human stromal cells results in the survival and proliferation of primary mantle cell lymphoma cells for at least 7 months compared to mantle cell lymphoma cells cultured alone. Mantle cell lymphoma-human stromal cell interactions resulted in activation of the B-cell activating factor/nuclear factor-κB signaling axis resulting in reduced apoptosis, increased mantle cell lymphoma migration and increased drug resistance. CONCLUSIONS: Direct mantle cell lymphoma-human stromal cell interactions support long-term expansion and increase the drug-resistance of primary mantle cell lymphoma cells. This is due in part to activation of the canonical and non-canonical nuclear factor κB pathways. We also demonstrated the ability of B-cell activating factor to augment CXCL12- and CXCL13-induced cell migration. Collectively, these findings demonstrate that human stromal cell-mantle cell lymphoma interactions play a pivotal role in the pathogenesis of mantle cell lymphoma and that analysis of mantle cell lymphoma-human stromal cell interactions may help in the identification of novel targets for therapeutic use.
BACKGROUND: There is increasing evidence that stromal cell interactions are required for the survival and drug resistance of several types of B-cell malignancies. There is relatively little information regarding the role of the bone marrow/lymphoid microenvironment in the pathogenesis of mantle cell lymphoma. In this study we investigated the interaction of primary mantle cell lymphoma cells with stromal cells in an ex vivo co-culture system. DESIGN AND METHODS: The murine stromal cell line MS-5 and human bone marrow mesenchymal stromal cells were each co-cultured with primary mantle cell lymphoma cells for up to 7 months. Mantle cell lymphoma cultures alone or combined with human stromal cells were analyzed for cell number, cell migration, nuclear factor-κB activation and drug resistance. RESULTS: Co-culture of mantle cell lymphoma cells and human stromal cells results in the survival and proliferation of primary mantle cell lymphoma cells for at least 7 months compared to mantle cell lymphoma cells cultured alone. Mantle cell lymphoma-human stromal cell interactions resulted in activation of the B-cell activating factor/nuclear factor-κB signaling axis resulting in reduced apoptosis, increased mantle cell lymphoma migration and increased drug resistance. CONCLUSIONS: Direct mantle cell lymphoma-human stromal cell interactions support long-term expansion and increase the drug-resistance of primary mantle cell lymphoma cells. This is due in part to activation of the canonical and non-canonical nuclear factor κB pathways. We also demonstrated the ability of B-cell activating factor to augment CXCL12- and CXCL13-induced cell migration. Collectively, these findings demonstrate that human stromal cell-mantle cell lymphoma interactions play a pivotal role in the pathogenesis of mantle cell lymphoma and that analysis of mantle cell lymphoma-human stromal cell interactions may help in the identification of novel targets for therapeutic use.
Authors: T Lwin; L A Hazlehurst; Z Li; S Dessureault; E Sotomayor; L C Moscinski; W S Dalton; J Tao Journal: Leukemia Date: 2007-05-03 Impact factor: 11.528
Authors: T Lwin; L A Crespo; A Wu; S Dessureault; H B Shu; L C Moscinski; E Sotomayor; W S Dalton; J Tao Journal: Leukemia Date: 2008-10-09 Impact factor: 11.528
Authors: Seok Jin Kim; Seung Jin Lee; In Young Choi; Yong Park; Chul Won Choi; In Sun Kim; Woosung Yu; Hee Sang Hwang; Byung Soo Kim Journal: Eur J Haematol Date: 2008-05-27 Impact factor: 2.997
Authors: Roger K Strair; Mecide Gharibo; Dale Schaar; Arnold Rubin; Jonathan Harrison; Joseph Aisner; Hsin-Ching Lin; Yong Lin; Lauri Goodell; Monika Anand; Binaifer Balsara; Liesel Dudek; Arnold Rabson; Daniel J Medina Journal: Clin Cancer Res Date: 2008-11-15 Impact factor: 12.531
Authors: Catherine A Tucker; Anita I Kapanen; Ghania Chikh; Brad G Hoffman; Alastair H Kyle; Ian M Wilson; Dana Masin; Randy D Gascoyne; Marcel Bally; Richard J Klasa Journal: Mol Cancer Ther Date: 2008-03-28 Impact factor: 6.261
Authors: Mohamed Rahmani; Mandy Mayo Aust; Elisa C Benson; LaShanale Wallace; Jonathan Friedberg; Steven Grant Journal: Clin Cancer Res Date: 2014-07-28 Impact factor: 12.531
Authors: Betty Y Chang; Michelle Francesco; Martin F M De Rooij; Padmaja Magadala; Susanne M Steggerda; Min Mei Huang; Annemieke Kuil; Sarah E M Herman; Stella Chang; Steven T Pals; Wyndham Wilson; Adrian Wiestner; Marcel Spaargaren; Joseph J Buggy; Laurence Elias Journal: Blood Date: 2013-08-12 Impact factor: 22.113